About
Medibyt offers an AI-powered platform for cardiopulmonary exercise testing (CPET) that automates interpretation and streamlines clinical workflows. Its flagship product, CPETWise, transforms complex physiological data into structured, clinician-ready reports within minutes, reducing analysis time from nearly an hour to just a few minutes. Compatible with existing metabolic systems, the cloud-based solution supports remote diagnostics and integrates seamlessly into hospital and outpatient settings. Developed with input from leading cardiopulmonary experts, CPETWise enhances diagnostic accuracy, increases testing throughput, and enables broader access to CPET in routine care and clinical research
Funding history · 1 round · $350K total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was Medibyt founded?
- Medibyt was founded in May 2024.
- What is Medibyt's primary product?
- Medibyt's flagship product is CPETWise, an AI-powered platform for cardiopulmonary exercise testing (CPET) interpretation.
- What is the core function of Medibyt's CPETWise platform?
- CPETWise automates the interpretation of complex physiological data from cardiopulmonary exercise tests, transforming it into structured, clinician-ready reports within minutes.
- What is Medibyt's current funding stage?
- Medibyt is currently in the Pre-Seed funding stage.
- How much grant funding has Medibyt received?
- In August 2024, Medibyt received a grant of $350,000 from the IIA.
- What is Medibyt's total amount raised in USD?
- Medibyt has raised a total of $350,000 USD.
- How many employees does Medibyt currently have?
- Medibyt currently has 3 employees.
- Which geographic markets does Medibyt target?
- Medibyt targets geographic markets including Canada, Europe, North America, and China.
- What technologies does Medibyt utilize?
- Medibyt utilizes Artificial Intelligence and Machine Learning technologies.